<DOC>
	<DOCNO>NCT02786342</DOCNO>
	<brief_summary>Sorafenib represent standard care advance hepatocellular carcinoma ( HCC ) . However , molecular predictor sorafenib efficacy yet identify . The primary aim study validate prognostic predictive role eNOS , Ang2 , HIF-1 , VEGF VEGFR polymorphism relation clinical outcome ( progression-free survival , PFS ) HCC patient treat sorafenib .</brief_summary>
	<brief_title>Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib</brief_title>
	<detailed_description>Sorafenib multikinase inhibitor act vascular endothelial growth factor receptor ( VEGFR ) platelet-derived growth factor receptor beta ( PDGFRβ ) involve tumor cell proliferation tumor angiogenesis . Angiogenesis cascade link sequential step ultimately lead tumour neovascularisation . Preclinical data suggest significant HCC growth dependent angiogenesis , increase tumour dimension may induce vascular endothelial cell proliferation . Vascular endothelial growth factor ( VEGF ) -driven pathway demonstrate play major role tumour angiogenesis . In fact , VEGF potent permeability factor promote cell migration invasion endothelial growth factor stimulate endothelial cell proliferation , induce bud new blood vessel around grow tumour mass . Single nucleotide polymorphism ( SNPs ) VEGF VEGF receptor ( VEGFR ) gene also correlate tumour neoangiogenesis different biological mechanism . In ALICE-1 study HCC patient receive sorafenib test VEGF-A , VEGF-C VEGFR-1,2,3 SNPs . At univariate analysis VEGF-A allele C rs25648 , T rs833061 , C rs699947 , C rs2010963 , VEGF-C alleles T rs4604006 , G rs664393 , VEGFR-2 alleles C rs2071559 , C rs2305948 significant predictor PFS overall survival ( OS ) . At multivariate analysis rs2010963 , rs4604006 Barcelona Clinic Liver Cancer ( BCLC ) stage result independent factor influence PFS OS . In ALICE-2 study SNPs hypoxia inducible factor 1α ( HIF-1α ) statistically significant PFS OS . The extended analysis VEGF VEGFR SNPs confirm result ALICE-1 study . The presence GG genotype rs12434438 ( HIF-1α ) select population particularly poor outcome independently clinical effect two VEGF SNPs ( PFS : 2.6 month , p &lt; 0,0001 ; OS : 6.6 month , p &lt; 0,0001 ) . In ePHAS study train cohort 41 HCC patient validation cohort 87 patient receive sorafenib analyze . At univariate analysis , patient homozygous endothelial nitric oxide synthase ( eNOS ) haplotype ( HT1 : T-4b eNOS-786/eNOS VNTR ) low median PFS ( 2.6 vs. 5.8 month , p &lt; 0.0001 ) OS ( 3.2 vs.14.6 month , p = 0.024 ) haplotype . These data confirm validation set patient homozygous HT1 low median PFS ( 2.0 vs. 6.7 month , p &lt; 0.0001 ) OS ( 6.4 vs.18.0 month , p &lt; 0.0001 ) . On basis premise prospective study aim validate potential role eNOS , VEGF , VEGFR , HIF-1 Ang2 polymorphism patient HCC treat sorafenib .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>1 . Signed date informed consent . 2 . Ability understand willingness sign write informed consent document . 3 . Male Female , age &gt; 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less . 5 . Life expectancy 12 week . 6 . Adequate hematologic function . 7 . Patients require least one untreated target lesion could measure one dimension , accord Response Evaluation Criteria Solid Tumors ( RECIST version 1.1 ) . 8 . Concomitant antiviral systemic therapy allow . 9 . Resolution acute toxic effect prior local treatment . 10 . HCC diagnose accord AASLD and/or EASL criterion . 1 . Previous concurrent cancer distinct primary site histology HCC . 2 . Renal failure require hemo peritoneal dialysis . 3 . Presence recent ( &lt; 6 month ) current cardiac failure Known history human immunodeficiency virus ( HIV ) infection . 4 . Known central nervous system tumor include metastatic brain disease . 5 . Patients clinically significant gastrointestinal bleeding within 30 day prior study entry . 6 . Any prior local therapy within 4 week study entry . 7 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>HCC</keyword>
	<keyword>Angiogenesis</keyword>
	<keyword>Polymorphisms</keyword>
</DOC>